Publications by authors named "Patrick P Gleason"

Claim this Profile
A
AMCP real-world evidence standards: Overcoming barriers to using real-world evidence in US payer decision-making.
Catherine M Lockhart, Elizabeth Powers, Brian Sweet, Patrick P Gleason, Diana Brixner

J Manag Care Spec Pharm· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey.
James T Kenney, Patrick P Gleason

J Manag Care Spec Pharm· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.
Patrick P Gleason, Benjamin Y Urick, Landon Z Marshall, Nicholas Friedlander, Yang Qiu

J Manag Care Spec Pharm· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria.
Kelly C Broderick, James P Burke, Jesse Fishman, Patrick P Gleason

J Manag Care Spec Pharm· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.
Landon Z Marshall, Rachel Espinosa, Catherine I Starner, Patrick P Gleason

J Manag Care Spec Pharm· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug super spender tsunami: An integrated medical and pharmacy benefits assessment.
Catherine I Starner, Kevin Bowen, Patrick P Gleason

J Manag Care Spec Pharm· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical Costs and Health Care Utilization Among Self-Insured Members with Carve-In Versus Carve-Out Pharmacy Benefits.
Julia J Smith, Yang Qiu, Steve V Lam, Chondra M Lockwood, Cheryl Pegus, Patrick P Gleason

J Manag Care Spec Pharm· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spinal Muscular Atrophy Therapies: ICER Grounds the Price to Value Conversation in Facts.
Catherine I Starner, Patrick P Gleason

J Manag Care Spec Pharm· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical Next Steps in Improving Value Measurement and Use.
Daniel A Ollendorf, Sachin Kamal-Bahl, Patrick P Gleason, Suzanne Schrandt, Newell McElwee

Value Health· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Value Frameworks-What's New?
Richard J Willke, Richard H Chapman, Joshua J Seidman, Lowell E Schnipper, Patrick P Gleason

Value Health· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of a Controlled Substance Scoring Algorithm with Health Care Costs and Hospitalizations: A Cohort Study.
Catherine I Starner, Yang Qiu, Pinar Karaca-Mandic, Patrick P Gleason

J Manag Care Spec Pharm· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of provider mailings on medication adherence by Medicare Part D members.
Bijan J Borah, Yang Qiu, Nilay D Shah, Patrick P Gleason

Healthc (Amst)· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir initial therapy abandonment and manufacturer coupons in a commercially insured population.
Taruja D Karmarkar, Catherine I Starner, Yang Qiu, Kristen Tiberg, Patrick P Gleason

Am J Manag Care· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specialty drug coupons lower out-of-pocket costs and may improve adherence at the risk of increasing premiums.
Catherine I Starner, G Caleb Alexander, Kevin Bowen, Yang Qiu, Peter J Wickersham, Patrick P Gleason

Health Aff (Millwood)· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of a drug utilization review program on high-risk use of prescription controlled substances.
Matthew Daubresse, Patrick P Gleason, Yi Peng, Nilay D Shah, Stephen T Ritter

Pharmacoepidemiol Drug Saf· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health plan utilization and costs of specialty drugs within 4 chronic conditions.
Patrick P Gleason, G Caleb Alexander, Catherine I Starner, Stephen T Ritter, Holly K Van Houten

J Manag Care Pharm· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dalfampridine prior authorization program: a cohort study.
Patrick P Gleason, Jill Phillips, Beckie A Fenrick, Ana Delgado-Riley, Catherine I Starner

J Manag Care Pharm· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
Alexandra Tungol, Catherine I Starner, Brent W Gunderson, Jeremy A Schafer, Yang Qiu, Patrick P Gleason

J Manag Care Pharm· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rosiglitazone prior authorization safety policy: a cohort study.
Catherine I Starner, Beckie Fenrick, John Coleman, Peter Wickersham, Patrick P Gleason

J Manag Care Pharm· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Price increases and new drugs drive increased expenditures for multiple sclerosis.
Jeremy A Schafer, Brent W Gunderson, Patrick P Gleason

J Manag Care Pharm· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.
Jeremy A Schafer, Nicole K Kjesbo, Patrick P Gleason

J Manag Care Pharm· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacy students' views of managed care pharmacy and PBMS: should there be more exposure to managed care in the pharmacy curriculum?
Amy L Pittenger, Catherine I Starner, Kaj Thompson, Patrick P Gleason

J Manag Care Pharm· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dronedarone: current evidence and future questions.
Jeremy A Schafer, Nicole K Kjesbo, Patrick P Gleason

Cardiovasc Ther· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
Patrick P Gleason, Catherine I Starner, Brent W Gunderson, Jeremy A Schafer, H Scott Sarran

J Manag Care Pharm· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of the relationship between the implementation of a newly designed prescription drug label at Target pharmacies and health outcomes.
William H Shrank, Amanda Patrick, Patrick P Gleason, Claire Canning, Carol Walters

Med Care· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis